Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Next Previous
Trial Profile

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lifileucel (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Iovance Biotherapeutics

Most Recent Events

  • 06 Aug 2026 According to an Iovance Biotherapeutics media release, Enrollment is nearly complete in the pivotal cohorts and program updates are expected in 4Q26. A supplemental Biologics License Application (sBLA) submission is planned in 2027.
  • 07 May 2026 According to an Iovance Biotherapeutics media release, the company expects to complete enrollment in 2026 to support supplemental Biologics License Application (sBLA). Company also expects U.S. accelerated approval and launch in the second half of 2027.
  • 03 Nov 2025 According to an Iovance Biotherapeutics media release, the company will present additional data from the IOV-LUN-202 trial at an upcoming medical meeting in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top